Stricter review of high-risk devices to support Australia's HTA assessment
This article was originally published in RAJ Devices
Australia’s Therapeutic Goods Administration has been asked to introduce by 2011 more rigorous pre-market approval requirements for higher-risk devices to satisfactorily establish the safety of these products before they are assessed for cost and clinical benefits by health technology bodies1,2.
You may also be interested in...
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.
The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date.
EU regulators say that sponsors must complete their nitrosamine-related risk evaluations for all EU medicines containing chemically-synthesised active substances within the six-month timeframe.